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Immunotherapy can become a crucial therapeutic option to improve prognosis for lung can-
cer patients. First clinical trials with therapies targeting the programmed cell death receptor
PD-1 and its ligand PD-L1 have shown promising results in several solid tumors. However,
in lung cancer the diagnostic, prognostic and predictive value of these immunologic factors
remains unclear.
Method
The impact of both factors was evaluated in a study collective of 321 clinically well-anno-
tated patients with non-small lung cancer (NSCLC) using immunohistochemistry.
Results
PD-1 expression by tumor infiltrating lymphocytes (TILs) was found in 22%, whereas tumor
cell associated PD-L1 expression was observed in 24% of the NSCLC tumors. In Fisher’s
exact test a positive correlation was found for PD-L1 and Bcl-xl protein expression (p = 0.013).
Interestingly, PD-L1 expression on tumor cells was associated with improved overall survival
in pulmonary squamous cell carcinomas (SCC, p = 0.042, log rank test), with adjuvant therapy
(p = 0.017), with increased tumor size (pT2-4, p = 0.039) and with positive lymph node status
(pN1-3, p = 0.010). These observations were confirmed by multivariate cox regression
models.
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Conclusion
One major finding of our study is the identification of a prognostic implication of PD-L1 in
subsets of NSCLC patients with pulmonary SCC, with increased tumor size, with a positive
lymph node status and NSCLC patients who received adjuvant therapies. This study pro-
vides first data for immune-context related risk stratification of NSCLC patients. Further
studies are necessary both to confirm this observation and to evaluate the predictive value
of PD-1 and PD-L1 in NSCLC in the context of PD-1 inhibition.
Introduction
Lung cancer remains one of the most common and one of the most lethal cancers worldwide
[1]. Throughout the last decade distinct molecular factors were identified as driving tumor
growth and spread and/or as being prognostic in non-small cell lung cancer (NSCLC). Several
attempts followed to specifically target these factors and thereby influence the clinical course of
disease. Molecular based therapies targeting epidermal growth factor receptor (EGFR) mutants
[2,3] or ALK rearrangements [4] were shown to improve the outcome within well-defined sub-
groups of non-squamous cell carcinoma patients. So far, only for a minority of all patients, tar-
getable genetic alterations have been identified. NSCLC patients with progressive disease and
without targetable alterations are treated with traditional chemotherapies. The majority of
them suffers from chemotherapy-associated toxicities and poor overall survival due to chemo-
therapy resistance. The recognition of cancer by the immune system and mechanisms of cancer
to escape the immune control are areas of increasing research interest. To enlarge our thera-
peutic armamentarium, new potent antigens need to be identified. In the future, novel and
modified immunotherapeutic concepts might improve cancer cell recognition for effective
tumor control.
Although an increased CD4+/CD8+ cell infiltration of the tumor stroma has previously been
shown to represent a favorable prognostic factor in NSCLC [5], ineffective therapeutic
approaches with IL-2 [6] and interferon [7] have led to the conclusion that NSCLC is non-
immunogenic. Recent gains of information in the field of tumor immunology include identifi-
cation of key regulators of immune responses with broad impact on natural and therapeutic
antitumor immune responses. The best-characterized immunological checkpoints with a
major impact on both cancer growth and cancer therapy are cytotoxic T-lymphocyte antigen 4
(CTLA-4) and programmed death receptor 1 (PD-1) and their respective ligands. Both recep-
tors (i.e. CTLA-4 and PD-1) inhibit T cell activation through distinct and potentially synergis-
tic mechanisms. While CTLA-4 fails to downregulate the survival gene Bcl-xl, PD-1
engagement is suggested to induce T cell apoptosis [8]. The PD-1 receptor is expressed by
CD4+ and CD8+ lymphocytes, regulatory T cells (Tregs) and B lymphocytes [9]. Upregulation
of PD-1 modulates peritumoral inflammatory processes [10]. Consequently, binding of PD-1
by the two major ligands PD-L1 (CD274) or PD-L2 (CD 273) inhibits cytokine production.
Inflammatory cytokines are reported to induce PD-L1 expression in tumor cells. PD-L1 inter-
acts with PD-1 on T cells and downregulates T cell effector functions. This mechanism can
enable cancer cells to evade host immune surveillance. Indeed, in several tumor types,
increased PD-1 levels were found in tumor infiltrating lymphocytes (TILs) [11]. Besides adap-
tive PD-L1 upregulation in an inflammatory cytokine milieu, tumors can have innate potential
to inactivate PD-1 by oncogene driven PD-L1 tumor expression [12]. Antibodies against the
PD-1-pathway have been successfully applied to reverse T cell tolerance of malignant cells and
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induce tumor regression [12]. In first clinical studies, anti-PD-1 antibodies have shown activity
in some NSCLC patients [13]. While these antibodies are undergoing clinical evaluation in
lung cancer and other malignancies, the concrete biological significance of PD-1 and PD-L1
expression in cancer remains unclear. PD-L1-positivity was found to be associated with an
inflammatory tumor microenvironment in lung cancers with squamous cell carcinoma [14] or
adenocarcinoma histology [15]. Recently, one study revealed high PD-L1 expression by tumor
cells to predict complete response as evaluated by histopathology to pre-operative chemother-
apy in breast cancer [16]. In the context of the emerging PD-1 pathway inhibitors, the particu-
lar characteristics of patients with expected therapeutic response to these agents still need to be
defined.
The present study aims at the evaluation of the prognostic significance of PD-1 expression
in TILs and PD-L1 expression in NSCLC tumor cells in a large study collective of NSCLC
using immunohistochemistry, with a particular emphasis on clinicopathological parameters.
Methods
Study population
Clinical follow up information and sufficient tumor material of 321 curatively resected NSCLC
patients (median age: 66 years) from the Thoracic Departments in Ostercappeln, Germany
(study collective I; n = 265 NSCLC tissue samples) and Mainz, Germany (study collective II;
n = 56 NSCLC tissue samples) were collected. Approval of the study by the Ethical committee
of Münster and Mainz were obtained for the collection of paraffin embedded tissue samples for
biomarker testing. Due to the retrospective, anonymized character of the analysis, written con-
sent was not required. Clinical TNM staging (including clinical examination, CT scans, sonog-
raphy, endoscopy, MRI, bone scan) was based on IUCC/AJCC recommendations. Patients
with stage IV, R1 or R2 resection status or with non-specified tumor histology (e.g. NSCLC not
otherwise specified) were excluded from our analysis. In terms of definite tumor staging, path-
ological exploration was carried out post-surgically. Primary pulmonary lesions were patholog-
ically classified based on the WHO 2004 guidelines; 149 specimens were classified as squamous
cell carcinoma, 125 as adenocarcinoma and 47 as large cell carcinoma. Regular follow-up was
performed for all patients, including systemic re-staging after 3, 6, 12, 18, 24, 36, 48 etc. months
or earlier, if clinically required. Survival time was either computed from the date of histological
diagnosis to death or to the date of last contact. Baseline information of the NSCLC population
is shown in Table 1.
Immunohistochemistry
Tissue microarrays were generated from formalin-fixed, paraffin-embedded tissue specimens
(FFPE). In detail, three biopsy needle cores (core diameter at least 0.6 mm) of each tumor care-
fully selected to appropriately represent potential tumor heterogeneity were transferred to a
recipient paraffin block as described [17]. For immunohistochemical analyses TMA slides were
steam heated for 30 minutes in pH 6 citrate buffers, and subsequent immunostaining was per-
formed with a 25 min incubation period of the primary antibody (DakoAutostainer, Den-
mark). The following primary monoclonal antibodies were applied: PD-1 (Abcam, ab 52587,
mouse IgG1, clone NAT 105, 1:50), PD-L1 (Cell Signaling Technology, #13684 clone E1L3N,
rabbit IgG1, 1:500), Bcl-2 (Santa Cruz Biotechnology, clone 100, mouse IgG1, 1:100) [18], Bcl-
xl (Santa Cruz Biotechnology, clone H-5, epitope: C-terminus, mouse IgG1, 1:1000) [18], and
ki-67 (Dako, M7240, clone MIB-1, mouse IgG1, 1:100). Immunoreaction was visualized with a
biotinylated secondary antibody (LSAB/AP, #K5005 Dako) including the Red chromogen,
according to the manufacturer. Finally, TMAs were counterstained with hematoxylin and
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covered with Cytoseal (Thermo Scientific, USA). Tonsillar tissue was employed as control for
PD-1, PD-L1, Bcl-2 and ki-67 stainings, colon cancer tissue was used for the Bcl-xl. In accor-
dance with previously published approaches in the field [19], the percentages of PD-1 positive
lymphocytes and PD-L1 positive tumor cells were assessed using a semiquantitative score con-
sidering 0 as negative, 1 as weak, 2 as moderate and 3 as high. Tumors were evaluated as PD-L1
positive if 5% of the tumor cells displayed at least moderate staining. The tumor was evalu-
ated as PD-1 positive if 5% of the lymphocytes displayed PD-1 staining. As described in
Schmidt et al., Bcl-2 [18], Bcl-xl [18] and ki-67 were evaluated according to Remmele’s Immu-
noreactive Score (IRS range, 1–12, [20]). Here, cases were considered as positive if IRS was
Table 1. Baseline characteristics of the study population (n = 321).
Parameter n % of non-missing values
Sex Male sex 251 78
Female sex 70 22
Smoking status Non-smoker 61 20
Smoker or ex-smoker 252 81
Performance status ECOG 0 59 19
ECOG I 235 76
ECOG >II 16 5
Adjuvant therapy Adjuvant chemotherapy 8 3
Adjuvant radiotherapy 38 12
Tumor stage Stage I 187 58
Stage II 83 26
Stage III 51 16




Lymph nodes status pN0 202 63
pN1-3 117 37
Tumor histology Squamous cell carcinoma 149 46
Adenocarcinoma 125 39
Large cell carcinoma 47 15
Tumor grading G1 5 2
G2 111 35
G3-4 199 63
Apoptosis Negative Bcl-2 expression 231 76
Positive Bcl-2 expression 74 24
Negative Bcl-xl expression 196 66
Positive Bcl-xl expression 101 34
EGFR mutation status No EGFR mutation 22 79
EGFR mutation 6 21
Proliferation (ki-67) Negative ki-67 expression 77 24
Positive ki-67 expression 244 76
PD-1 expression in tumor Inﬁltrating lymphocytes (TILs) negative lymphocytic expression 249 78
negative lymphocytic expression 72 22
PD-L1 expression in NSCLC negative tumor expression 244 76
positive tumor expression 77 24
doi:10.1371/journal.pone.0136023.t001
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greater than or equal to 3. Analysis of TMA slides was performed by at least two independent
investigators (L.H.S, T.S. and W.H.).
EGFR analysis
The full protocol for EGFR analysis was previously published by Schmidt et al. [18]. In brief,
DNA was extracted from FFPE tumor tissues and analyzed for EGFR mutations by Sanger
sequencing. The EGFR status of each patient’s tumor was assessed from the individual status of
all mutation types and recorded as one of the following: positive (mutation detected for at least
one of the mutation types assayed), negative (no mutation detected in any of the mutation
types assayed), or undetermined/ unknown (a positive or negative result could not be deter-
mined as per laboratory assessment).
Statistical Analysis
The study population was described by standard descriptive statistical measures. For categori-
cal variables, absolute and relative frequencies are reported. For continuous variables median
and interquartile range (IQR) are reported, respectively. Association of clinico-pathological
parameters with PD-1 and PD-L1 expression was tested using two-sided Fisher’s exact test.
Univariate overall survival analysis was performed using the Kaplan-Meier method and log
rank tests. A multivariable Cox proportional hazards model was fitted using a forward step-
wise variable selection (inclusion criteria: p-value of the likelihood ratio test0.05) to identify
independent prognostic factors for overall survival. We considered potential prognostic factors
that are tolerably complete (less than ten missing values, and with at least ten cases), to prevent
statistical problems emerging from low sample size and extreme values. Patients with missing
values in the cofactors were excluded from the analysis. All statistical tests were performed as
exploratory analyses on a local significance level of 0.05. Since multiplicity adjustment was not
carried out, no distinct overall significance level was ascertained. Hence, our findings may be
used to set up new hypotheses. SPSS (SPSS Statistics, Version 22.0 released 2013, IBM Corp.,
Armonk, NY) was used for all statistical analyses.
Results
Immunohistochemistry
The characteristics of the 321 NSCLC patients are summarized in Table 1. Due to tissue loss
immunohistochemical evaluation was not feasible in 16 cases for Bcl-2 and in 24 cases for Bcl-
xl. Positive PD-1 protein expression was found in 72 cases (22%) in tumor infiltrating lympho-
cytes (TILs). Fig 1 demonstrates representative immunohistochemical staining patterns for
normal lung tissue (Fig 1A), for control tonsillar tissue (Fig 1B) and for NSCLC (Fig 1C and
1D). PD-L1 was expressed by 24% of the NSCLC samples. Representative immunohistochemi-
cal staining patterns are given in Fig 1E–1H (Fig 1E: normal lung tissue, Fig 1F: control tonsil-
lar tissue, Fig 1G and 1H: NSCLC). Tumor cells displayed a cytoplasmic staining pattern for
PD-L1 (Fig 1H). Tumors with a PD-1 positive lymphocytic infiltrate displayed synchronous
PD-L1 expression in 17 cases (5%). In case of heterogeneity with regard to the infiltrating PD-1
positive TIL population or PD-L1 positive tumor cells the fraction of positive lymphocytes/
tumor cells was referred to the whole tumor tissue as represented by the selected tissue cores.
Of interest, PD-1 positive TILs were rarely observed within the epithelial tumor cell forma-
tions, but rather within the tumor stroma, independent from PD-L1 expression status. Beyond
PD-1 and PD-L1, immunohistochemical information for Bcl-2, Bcl-xl, ki-67 and EGFR muta-
tion were available for the study collective [18]: 74 tumors (24%) involved in the study
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collective expressed Bcl-2, 101 tumors (34%) expressed Bcl-xl and EGFR mutations (positive,
either at position 18, 19 or 21) were found for 6 patients (21%; Table 1). Of interest 16 samples
(5%) concomitantly had PD1 expressing TILs and displayed PDL1 in the tumor cells.
Clinicopathologic correlations
A positive correlation for PD-L1 tumor expression in NSCLC cells was found with Bcl-xl
expression (p = 0.013). While 18% of Bcl-xl negative tissue samples expressed PD-L1, expres-
sion rate was 32% in Bcl-xl positive NSCLC samples. Besides this observed correlation, we did
not find any other association for any of the other tested parameters (all p>0.05; Table 2).
Fig 1. Representative immunohistochemical staining results for PD-1 (A: normal lung tissue, negative
control; B: tonsillar tissue, positive control; C: PD-1-negative tumor infiltrating lymphocytes; D: PD-
1-positive tumor infiltrating lymphocytes in squamous cell carcinomas) and for PD-L1 (E: normal lung
tissue, negative control; F: tonsillar tissue, positive control; G: PD-L1 negative squamous cell
carcinomas; H: PD-L1 positive squamous cell carcinomas). All images at x20, inlay x40.
doi:10.1371/journal.pone.0136023.g001
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Table 2. Associations of clinicopathological variables with PD-1 (in TILs) or PD-L1 (in NSCLC cells).
Variables PD-1 (+) in TILs p-value* n
(%)
PD-L1 (+) in NSCLC p-value* n
(%)
Age p-value 0.887 0.580
<70 years 47 (22%) 49 (23%)
70 years 25 (23%) 28 (26%)
Sex p-value 0.260 0.637
Male sex 60 (24%) 62 (25%)
Female sex 12 (17%) 15 (21%)
Smoking status p-value 0.384 0.315
Non-smoker 10 (16%) 18 (30%)
Smoker or ex-smoker 57 (23%) 57 (23%)
Performance status p-value 0.120 0.867
ECOG 0 18 (31%) 15 (25%)
ECOG 1 52 (21%) 61 (24%)
Adjuvant therapy p-value 0.849 0.712
No adjuvant therapy 61 (22%) 65 (24%)
Adjuvant therapy 11 (24%) 12 (26%)
Tumor stage p-value 0.498 0.508
Stage I 39 (21%) 42 (23%)
Stage 1I 33 (25%) 35 (26%)
Tumor size p-value 0.664 0.481
pT1 24 (24%) 21 (21%)
pT2-4 48 (22%) 56 (25%)
Lymph nodes status p-value 0.489 0.892
pN0 43 (21%) 48 (24%)
pN1-3 29 (25%) 29 (25%)
Tumor histology p-value 0.505 0.089
Squamous cell carcinoma 36 (21%) 48 (28%)
Non squamous cell
carcinoma
36 (24%) 29 (20%)
Tumor grading p-value 1.000 0.786
< G2 25 (22%) 29 (25%)
 G2 44 (22%) 47 (24%)
Apoptosis p-value 0.523 0.162
Negative Bcl-2 expression 50 (22%) 52 (23%)
Positive Bcl-2 expression 19 (26%) 23 (31%)
p-value 0.464 0.013
Negative Bcl-xl expression 41 (21%) 36 (18%)
Positive Bcl-xl expression 25 (25%) 32 (32%)
EGFR mutation status p-value 0.288 1.000
No EGFR mutation 7 (32%) 8 (36%)
EGFR mutation 0 2 (33%)
Proliferation (ki-67) p-value 0.756 0.287
Negative ki-67 expression 16 (21%) 22 (29%)
Positive ki-67 expression 56 (23%) 55 (23%)
(Continued)
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PD-L1 expression indicates improved prognosis in NSCLC subgroups
For the tested factors PD-1 and PD-L1 univariate Kaplan–Meier estimates for the full study
collective did not demonstrate any significant effect on overall survival (OS). The p-values of
the Log rank test are displayed for both, PD-1 (in TILs) and PDL1 (in NSCLC tumor cells) in
Table 3 and in Fig 2 (Fig 2A: p-value for PD-1 in TILs = 0.421; Fig 2B: p-value for PD-L1 in
NSCLC tumor cells = 0.265). Likewise concomitant expression of both factors did not show
any relevant prognostic effect in the entire study cohort (p = 0.322; S1 Fig) as well as in sub-
group analysis regarding all other tested parameters (data not shown).
Subgroup analyses were performed for sex, age, smoking status, performance status, adju-
vant therapy, tumor histology, tumor grading, tumor stage, tumor size, lymph node status, Bcl-
2 expression, Bcl-xl expression, EGFR mutation status, PD-1 expression in tumor infiltrating
lymphocytes and PD-L1 expression in tumor cells. Here, stratified analysis identified PD-L1
expression in NSCLC tumor cells to be associated with improved prognosis for adjuvant ther-
apy (p = 0.017; Fig 2C), tumor histology (pulmonary squamous cell carcinoma; p = 0.042; Fig
2D), increased tumor size (pT2-4; p = 0.039; Fig 2E) and lymph node status (pN1-3; p = 0.010;
Fig 2F). A prognostic effect was found for PD-1-positive tumor infiltrating lymphocytes in
patients with non EGFR-mutated tumors (p = 0.018; Table 3). Due to the small number of
patients (n = 22 patients), this effect is most likely not of clinical significance. Apart from this
observation, further univariate subgroup analyses for PD-1 did not reveal any other relevant
prognostic effect (all p>0.05; Table 3).
Prognostic value of PD-1 and PD-L1
To determine the prognostic value of tumor infiltration by PD-1 positive lymphocytes and
PD-L1 expression by tumor cells, Cox proportional hazards models for comparison with estab-
lished prognostic factors were applied. As shown for the full study collective neither PD-1 nor
PD-L1 were of prognostic relevance (all p>0.05, Table 4). Here only age (HR (95%CI) = 1.545
(1.147–2.080); p = 0.005), tumor stage (HR (95%CI) = 1.986 (1.492–2.645); p<0.001) and sex
(HR (95%CI) = 1.658 (1.132–2.429; p = 0.006) were identified as prognostic parameters.
Subgroup analyses were performed to prove the observed subgroup-relevant effects for
PD-L1 with adjuvant therapy, tumor histology, tumor size and lymph node status. Cox regres-
sion models confirmed the observed positive prognostic effect of PD-L1 expression for adju-
vant therapy (HR (95%CI) = 0.353 (0.145–0.861); p = 0.012; Table 4), for tumor histology (HR
(95%CI) = 0.459 (0.252–0.833); p = 0.005; Table 4), for tumor size (HR (95%CI) = 0.556
(0.366–0.844); p = 0.004; Table 4) and for lymph node status (HR (95%CI) = 0.470 (0.268–
Table 2. (Continued)
Variables PD-1 (+) in TILs p-value* n
(%)
PD-L1 (+) in NSCLC p-value* n
(%)









PD-L1 expression in NSCLC p-value 1.000
negative tumor expression 55 (23%)
positive tumor expression 17 (22%)
*p values according to Fisher’s exact test.
doi:10.1371/journal.pone.0136023.t002
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0.825); p = 0.005; Table 4). For NSCLC patients who were not treated with adjuvant therapy
(S2A Fig), patients with non-squamous cell carcinomas (S2B Fig), patients with small tumor
sizes (pT1) or patients without lymphatic spread (pN0) no relevant prognostic effects were not
found.
Discussion
Blockade of inhibitory immune checkpoints is currently arising as a potential immunological
option for tumor therapy. Targeting the PD-1/PD-L1 pathway in lung cancer has shown prom-
ise to positively affect prognosis in first clinical studies [13,21]. A more detailed understanding
Table 3. Univariate Log-rank test results for the association of PD-1 (in TILs) or PD-L1 (in NSCLC cells) with overall survival for defined
subgroups.
Subgroups PD-1 (+) in TILs p-value* PD-L1 (+) in NSCLC p-value*
All 0.421 0.265
Age <70 years 0.7790.054 0.2040.768
70 years 0.7790.054 0.2040.768
Sex Male 0.7640.125 0.0820.300
Female 0.7640.125 0.0820.300
Smoking status No smoking history 0.444 0.626
Smoking history 0.324 0.358
Performance status ECOG 0 0.467 0.150
ECOG >I 0.749 0.780
Adjuvant therapy No adjuvant therapy 0.255 0.797
Adjuvant therapy 0.632 0.017
Tumor stage Stage I 0.237 0.967
Stage II-IV 0.807 0.052
Tumor size pT1 0.893 0.303
pT2-4 0.405 0.039
Lymph node status pN0 0.274 0.644
pN1-3 0.727 0.010
Tumor histology Non squamous cell carcinoma 0.108 0.685
Squamous cell carcinoma 0.619 0.042
Tumor grading < G2 0.763 0.226
 G2 0.249 0.663
Bcl-2 expression Negative Bcl-2 expression 0.226 0.440
Positive Bcl-2 expression 0.553 0.290
Bcl-xl expression Negative Bcl-xl expression 0.437 0.466
Positive Bcl-xl expression 0.475 0.712
EGFR mutation status No EGFR mutation 0.018 0.597
EGFR mutation 0.654
Proliferation (ki67) Negative ki-67 expression 0.908 0.607
Positive ki-67 expression 0.273 0.142
PD-1 expression in TILs Negative PD-1 expression 0.132
Positive PD-1 expression 0.465
PD-L1 expression in NSCLC Negative PD-L1 expression 0.194
Positive PD-L1 expression 0.579
*p values according to log rank test.
doi:10.1371/journal.pone.0136023.t003
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of the significance of the PD-1/PD-L1 pathway in this cancer is important to advance this
promising treatment modality to its full potential. In order to evaluate the prognostic impact of
tumor infiltration by PD-1 positive lymphocytes and PD-L1 expression by tumor cells, we per-
formed a systematic study in a well-defined collective of 321 NSCLC patients undergoing pri-
mary tumor resection without preceding neoadjuvant therapy. Only completely resected, non-
metastatic patients with a clear NSCLC histology were included for the statistical evaluation.
Tumor infiltration by PD-1 positive lymphocytes was detected in 22% of the tumor samples
and 24% of the tumors displayed positivity for PD-L1 with 16 samples (5%) showing synchro-
nous positivity for both. The finding concerning PD-L1 corresponds well to other published
studies, which report immunohistochemical expression rates of 25–65% for PD-L1 in tumors
of NSCLC patients [16,22–26]. Differences might be due to variabilities of the tumor microen-
vironment and to non-static expression at a single point of time [27]. To our knowledge, in
contrast to reports on PD-L1 expression in tumor cells, no comparable data regarding the
Fig 2. Prognostic impact of PD-L1 expression by tumor cells depends on tumor histology.Whereas for the full study collective (n = 321 patients), no
prognostic effect was found, neither for PD-1 (A) nor for PD-L1 (B), patients who received adjuvant therapy (C), patients with pulmonary squamous cell
carcinomas (D), patients with pT2-T4 tumors (E) and patients with a positive lymph node status (pN1-3, F) had an increased overall survival.
doi:10.1371/journal.pone.0136023.g002
Table 4. Overall survival: Explanatory prognostic factors in a Cox proportional Hazardsmodel for the full study collective and for subgroups
depending on adjuvant therapy, tumor histology, tumor size and lymph node status. Included variables: PD-1 expression in tumor infiltrating lympho-
cytes (negative expression (ref.) vs. positive expression), PD-L1 expression in NSCLC cells (negative expression (ref.) vs. positive expression), sex (male
(ref.) vs. female), age (<70 years (ref.) vs.70 years), smoking status (no smoking history (ref.) vs. smoking history), adjuvant therapy (no adjuvant therapy
(ref.) vs. adjuvant therapy), tumor histology (squamous cell carcinoma (ref.) vs. non squamous cell carcinoma), tumor stage (stage I (ref.) vs. stage II-IV),
tumor size (pT1 (ref.) vs.pT2), lymph node status (pN0 (ref.) vs. pN1-3) and grading (<G2 (ref.) vs.G2).
Prognostic groups Prognostic factor p-value HR1(95% CI)2
All NSCLC patients (n = 301) Age 0.005 1.545 (1.147–2.080)
Tumor stage <0.001 1.986 (1.492–2.645)
Sex 0.006 1.658 (1.132–2.429)
Adjuvant therapy No adjuvant therapy (n = 255) PD-1 0.035 0.659 (0.440–0.987)
Age 0.019 1.471 (1.070–2.021)
Tumor size 0.016 1.563 (1.074–2.275)
Tumor stage <0.001 1.928 (1.382–2.690)
Adjuvant therapy (n = 46) PD-L1 0.012 0.353 (0.145–0.861)
Tumor histology Non squamous cell carcinoma (n = 163) PD-1 0.030 0.561 (0.322–0.977)
Age 0.016 1.704 (1.118–2.598)
Sex 0.032 1.663 (1.028–2.688)
Tumor size 0.043 1.627 (1.001–2.646)
Lymph node status 0.001 2.049 (1.351–3.107)
Squamous cell carcinoma (n = 138) PD-L1 0.005 0.459 (0.252–0.833)
Tumor stage 0.002 1.929 (1.277–2.913)
Tumor size pT1 (n = 93) Sex 0.002 2.860 (1.361–6.010)
Tumor stage 0.005 2.615 (1.389–4.922)
pT2-4 (n = 208) PD-L1 0.004 0.556 (0.366–0.844)
PD-1 0.023 0.626 (0.410–0.954)
Age 0.041 1.429 (1.020–2.001)
Lymph node status 0.001 1.783 (1.279–2.486)
Lymph node status pN0 (n = 192) Age 0.009 1.671 (1.140–2.449)
Tumor size 0.004 1.809 (1.191–2.747)
pN1-3 (n = 109) PD-L1 0.005 0.470 (0.268–0.825)
doi:10.1371/journal.pone.0136023.t004
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infiltration levels with PD-1 positive cells have been published, yet. Moreover, no mechanistic
relation between the extent of PD-1 positive lymphocytic infiltration and PD-L1 positivity of
the tumor cells has been shown so far. Hence, we did not find any association between PD-1
positive TILs and PD-L1 positive tumor cells.
To test whether PD-1 and PD-L1 correlate with the activation of apoptotic pathways [8], we
analyzed associations for Bcl-2 and Bcl-xl. Here, positive associations were found for Bcl-xl
expression in the tumor cells and PD-L1 expression in tumor cells. However, the observed pos-
itive correlation for Bcl-xl (Fisher’s exact test; Table 2) was not found in the prognostic sub-
group analysis (log rank test; Table 3). So far, the impact of this observation is not clear and it
may not be relevant. While one study group reported PD-L1 expression to be associated with
adenocarcinoma histology [15] and another study reported it to be associated with squamous
cell carcinoma histology [14], our correlation anaylsis (Fisher’s exact test) supports the latter
observation. As shown before, we did not find any association between PD-L1 expression and
presence of EGFR mutations [26].
The prognostic analysis of the full study cohort, including all NSCLC histologies, did not
reveal any significant effect of tumor infiltration by PD-1 positive lymphocytes and/or PD-L1
expression of the tumor cells on overall survival (Fig 2A and 2B). However, a favorable prog-
nosis was found for PD-L1 expression in tumor cells for patients who received adjuvant ther-
apy, with pulmonary squamous cell carcinomas, higher T descriptor or lymph node metastasis
(Fig 2C and 2D). Beyond other prognostic variables such as age or tumor stage, multivariate
analyses confirmed PD-L1 expression in tumor cells to be a marker for an improved prognosis
for patients with these characteristics. For infiltration by PD1 positive lymphocytes borderline
prognostic effects were found in some multivariate subgroup analyses.
With respect to the recent literature, previous studies regarding the prognostic role of PD-L1
for NSCLC patients have been controversial. There are studies suggesting a negative prognostic
value [15,24], whereas others did not find any prognostic impact [22,24,26]. Recently, one larger
study including 340 NSCLC patients reported both, tumor PD-L1 protein and PD-L1 mRNA
expression to be associated with increased local lymphocytic infiltrates and increased overall sur-
vival [14]. Our results are in agreement with this and further previous reports in other tumor
types. An association between PD-L1 expression with an improved overall survival was found in
metastasized malignant melanoma [28], colorectal cancer [29], and breast cancer [30]. As in our
study, all reported patients did not receive anti-PD1/PD-L1 therapies.
The biology of an association between PD-L1 expression and better outcome in patients
with adjuvant therapy, lymphatic metastasis, and squamous cell carcinoma is not well under-
stood. A potential explanation is that the favorable prognostic impact of PD-L1 upregulation
in these conditions may indicate the presence of a mixed immune cell infiltrate containing
cytotoxic and regulatory T cells and reflect a partially dysbalanced local cellular immune
response, which still contributes to antitumor immune control. In this case, a specific therapeu-
tic interference with the PD-1/PD-L1 pathway may unleash a cytotoxic T cell response in the
tumor. Thus, more detailed studies on the phenotype of infiltrating immune cells, in particular
with regard to T cell subpopulations, seem to be important. Of interest, neither the prolifera-
tion marker Ki-67 nor the anti-apoptotic factors were associated with the prognostic effect of
PD-L1 expression, highlighting that regulation of proliferation and apoptosis may be indepen-
dent form immunologic mechanisms.
With respect to therapeutic interventions, inhibition of PD-1/PD-L1 is expected to become
a powerful therapeutic alternative for NSCLC [31]. Overall, for advanced NSCLC patients, the
overall response rate (ORR) for PD-1 inhibitory drugs was 24%, whereas for NSCLC patients
with PD-L1 expression the ORR was 100% compared to 15% for PD-L1 negative tumors [32].
The latter study argues in favour of the evaluation of PD-L1 expression as a selective
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biomarker, and the analysis of PD-L1 in NSCLC could serve as predictor for response to PD-1
pathway inhibition and additionally as a prognostic marker for improved clinical outcome
[33].
Our oligocentric study has several limitations, such as its retrospective nature and the
potential risk of bias resulting from variable treatment protocols, regarding both surgical pro-
cedures and adjuvant therapies. The issue of representative tissue sample selection for TMAs
was addressed in a previous study [18]. To reduce sampling errors, each patient’s tumor was
represented by three tissue cores sampled from different tumor areas covering potential histo-
logical heterogeneity.
In conclusion, PD-L1 is a prognostic factor for NSCLC patients with squamous cell carci-
noma histology, lymph node metastasis and patients treated in an adjuvant setting. It is feasible
to hypothesize that patients with PD-L1 expression profit the most in an adjuvant treatment
setting, however the sample size of our study is too small to answer this clinically important
issue. Prospective studies are required to confirm this observation. If our observation is con-
firmed by further and prospective analyses, PD-L1 expression could contribute to adequate
risk stratification. Beyond conventional therapies, PD-L1 expression likely represents a critical
biomarker for predicting the individual probability of response to treatment with PD-1/PD-L1
pathway inhibitory agents. Prospective assessment of this parameter along with clinical trials
will help to establish its significance in this context and allow selecting patients with a high like-
lihood to respond to various therapeutic interventions.
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